Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00625456 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | completed | Phase 1 | 23 | Jennerex BiotherapeuticsINDUSTRY | 2 | Dec 3, 2015 | clinicaltrials |
| NCT02417948 | Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans | completed | N/A | 143 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma |
| terminated |
| Phase 2 |
| 31 |
| Bristol-Myers SquibbINDUSTRY |
| 5 |
| Nov 30, 2015 |
| clinicaltrials |
| NCT00833807 | Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver | completed | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | terminated | Phase 1 / Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01474551 | Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT02608437 | A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients(NIBIT-M4) | unknown | Phase 1 | 19 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT00006126 | Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 0 | Nov 13, 2015 | clinicaltrials |
| NCT00096382 | Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00704938 | Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer | terminated | Phase 2 | 3 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00706992 | Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00923195 | Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01160445 | Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01273181 | MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00110019 | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 3 | 823 | National Cancer Institute (NCI)NIH | 2 | Oct 19, 2015 | clinicaltrials |
| NCT00665470 | Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00749684 | Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083) | completed | — | 138 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 19, 2015 | clinicaltrials |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 15, 2015 | clinicaltrials |
| NCT00276536 | Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma(IFNa) | completed | Phase 1 | 35 | The Cleveland ClinicOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT00612664 | Phase II, 2nd Line Melanoma - RAND Monotherapy | completed | Phase 2 | 158 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 12, 2015 | clinicaltrials |
| NCT00093678 | Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer | withdrawn | N/A | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT01295931 | Nuclear and Near-Infrared (NIR) Imaging in Melanoma | completed | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01882946 | Safety and Efficacy Study of DCVax-Direct in Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Northwest BiotherapeuticsINDUSTRY | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01376713 | Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma | completed | Phase 2 | 10 | Medical University of ViennaOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00002973 | Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma | completed | Phase 2 | 34 | University of Wisconsin, MadisonOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00085306 | Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma | completed | Phase 2 | 21 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT01783431 | Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells | terminated | Phase 1 | 1 | Medical University of South CarolinaOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00317759 | Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 1, 2015 | clinicaltrials |
| NCT00403377 | Investigation of a Behavioral Substitute for Sunbathing | completed | Phase 1 / Phase 2 | 307 | University of Massachusetts, WorcesterOTHER | 1 | Oct 1, 2015 | clinicaltrials |
| NCT00432107 | A Study to Assess APO866 for the Treatment of Advanced Melanoma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Sep 29, 2015 | clinicaltrials |
| NCT01119599 | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2015 | clinicaltrials |
| NCT00832533 | The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure | completed | — | 9 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01008527 | Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 | completed | Phase 1 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 24, 2015 | clinicaltrials |
| NCT01765569 | A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma | completed | Phase 1 | 29 | Hoffmann-La RocheINDUSTRY | 5 | Sep 23, 2015 | clinicaltrials |
| NCT01045915 | Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma(AMEP) | terminated | Phase 1 | 5 | Valerio TherapeuticsINDUSTRY | 3 | Sep 11, 2015 | clinicaltrials |
| NCT01764009 | Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma(AIMM) | withdrawn | Phase 1 / Phase 2 | 0 | Valerio TherapeuticsINDUSTRY | 2 | Sep 11, 2015 | clinicaltrials |
| NCT00818480 | An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 | completed | Phase 2 | 10 | Astellas Pharma IncINDUSTRY | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01009775 | A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma | completed | Phase 2 | 64 | Astellas Pharma IncINDUSTRY | 2 | Sep 4, 2015 | clinicaltrials |
| NCT00275496 | Multicenter Selective Lymphadenectomy Trial (MSLT) | completed | Phase 3 | 2,001 | Saint John's Cancer InstituteOTHER | 0 | Sep 2, 2015 | clinicaltrials |
| NCT01729663 | Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients | unknown | Phase 2 / Phase 3 | 108 | Laboratorio Pablo Cassara S.R.L.INDUSTRY | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00139360 | Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma | completed | Phase 2 | 35 | Haukeland University HospitalOTHER | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00723710 | Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600) | completed | — | 299 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 26, 2015 | clinicaltrials |
| NCT01107418 | A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma | completed | Phase 1 | 52 | Hoffmann-La RocheINDUSTRY | 2 | Aug 26, 2015 | clinicaltrials |
| NCT00978913 | Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma | completed | Phase 1 | 31 | Inge Marie SvaneOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00937625 | T-cell Based Immunotherapy for of Melanoma | completed | Phase 1 / Phase 2 | 31 | Inge Marie SvaneOTHER | 1 | Aug 18, 2015 | clinicaltrials |
| NCT00866177 | MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 167 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2015 | clinicaltrials |
| NCT02511119 | Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of Melanoma | unknown | — | 300 | Maimónides Biomedical Research Institute of CórdobaOTHER | 0 | Jul 30, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Dec 3, 2015source: clinicaltrials